Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: A multicenter phase 2 study

61Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND. Cetuximab, an immunoglobulin (Ig) G1 chimeric monoclonal antibody against the epidermal growth factor receptor, has demonstrated evidence of activity in nonsmall cell lung cancer (NSCLC). When administered in combination with carboplatin and docetaxel, a commonly used regimen for advanced NSCLC, cetuximab has exhibited synergistic interaction in preclinical studies. Therefore, a phase 2 study was conducted to evaluate the efficacy of the combination of cetuximab, carboplatin, and docetaxel for the treatment of advanced NSCLC. METHODS. Chemotherapy-naïve patients aged ≥18 years with stage IIIB (with effusion) or stage IV NSCLC received cetuximab (at a dose of 400 mg/m2 on Day 1 and 250 mg/m2 on Days 8 and 15) plus docetaxel (at a dose of 75 mg/m2 on Day 1) and carboplatin (area under the concentration vs time curve [AUC] = 6 on Day 1) every 21 days for up to 6 cycles (graded according to the American Joint Committee on Cancer Staging System). Thereafter, patients without evidence of disease progression were continued on single-agent cetuximab for a maximum of 1 year or until disease progression. The primary endpoint was response rate. RESULTS. Eighty patients were enrolled. The median number of cycles administered was 4 (range, 1-6 cycles). The objective response rate was 15.2%, with a median progression-free survival of 4.6 months and a median overall survival of 10.3 months. The salient grades 3 of 4 adverse events were neutropenia (30%), hypotension (3%), hypokalemia (4%), and hypomagnesemia (3%). Twenty-five patients received single-agent cetuximab (median duration, 12 weeks) and this was well tolerated. CONCLUSIONS. The results of this large, multicenter, phase 3 study indicate that the novel combination of cetuximab with docetaxel and carboplatin demonstrate modest anticancer activity for patients with advanced and metastatic NSCLC and has an acceptable toxicity profile. © 2008 American Cancer Society.

References Powered by Scopus

New guidelines to evaluate the response to treatment in solid tumors

14954Citations
N/AReaders
Get full text

EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy

8909Citations
N/AReaders
Get full text

Cancer statistics, 2007

7682Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

1292Citations
N/AReaders
Get full text

Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities

370Citations
N/AReaders
Get full text

Targeted therapy in non-small-cell lung canceris it becoming a reality?

246Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Belani, C. P., Schreeder, M. T., Steis, R. G., Guidice, R. A., Marsland, T. A., Butler, E. H., & Ramalingam, S. S. (2008). Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: A multicenter phase 2 study. Cancer, 113(9), 2512–2517. https://doi.org/10.1002/cncr.23902

Readers over time

‘10‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

39%

Researcher 6

33%

Professor / Associate Prof. 3

17%

Lecturer / Post doc 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

58%

Agricultural and Biological Sciences 3

16%

Biochemistry, Genetics and Molecular Bi... 3

16%

Pharmacology, Toxicology and Pharmaceut... 2

11%

Save time finding and organizing research with Mendeley

Sign up for free
0